argenx SE (NASDAQ:ARGX) Shares Sold by Signaturefd LLC

Signaturefd LLC trimmed its holdings in shares of argenx SE (NASDAQ:ARGX) by 3.2% in the 4th quarter, HoldingsChannel.com reports. The fund owned 1,365 shares of the company’s stock after selling 45 shares during the quarter. Signaturefd LLC’s holdings in argenx were worth $519,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors and hedge funds have also bought and sold shares of the business. Nkcfo LLC lifted its stake in argenx by 22.1% during the 3rd quarter. Nkcfo LLC now owns 116 shares of the company’s stock valued at $57,000 after acquiring an additional 21 shares during the period. Genus Capital Management Inc. lifted its stake in argenx by 1.6% during the 3rd quarter. Genus Capital Management Inc. now owns 1,605 shares of the company’s stock valued at $789,000 after acquiring an additional 25 shares during the period. Daiwa Securities Group Inc. lifted its stake in shares of argenx by 2.8% in the 4th quarter. Daiwa Securities Group Inc. now owns 1,530 shares of the company’s stock valued at $582,000 after purchasing an additional 41 shares during the period. Sequoia Financial Advisors LLC lifted its stake in shares of argenx by 2.7% in the 3rd quarter. Sequoia Financial Advisors LLC now owns 1,752 shares of the company’s stock valued at $861,000 after purchasing an additional 46 shares during the period. Finally, CWM LLC lifted its stake in shares of argenx by 29.4% in the 3rd quarter. CWM LLC now owns 207 shares of the company’s stock valued at $102,000 after purchasing an additional 47 shares during the period. 60.32% of the stock is currently owned by institutional investors and hedge funds.

argenx Trading Down 0.0 %

Shares of ARGX opened at $375.00 on Thursday. argenx SE has a 12-month low of $327.73 and a 12-month high of $550.76. The firm has a 50-day moving average price of $386.72 and a 200 day moving average price of $418.48. The firm has a market capitalization of $22.29 billion, a P/E ratio of -72.96 and a beta of 0.65.

argenx (NASDAQ:ARGX) last announced its quarterly earnings data on Thursday, February 29th. The company reported ($1.68) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.23) by ($0.45). argenx had a negative net margin of 23.26% and a negative return on equity of 16.97%. The firm had revenue of $417.84 million during the quarter, compared to analysts’ expectations of $378.60 million. During the same period in the prior year, the company posted ($0.70) EPS. Equities research analysts predict that argenx SE will post -2.1 earnings per share for the current fiscal year.

Analyst Ratings Changes

ARGX has been the subject of several analyst reports. Wells Fargo & Company boosted their target price on shares of argenx from $472.00 to $478.00 and gave the company an “overweight” rating in a research note on Tuesday, February 20th. Scotiabank boosted their target price on shares of argenx from $402.00 to $408.00 and gave the company a “sector perform” rating in a research note on Tuesday, March 26th. Wolfe Research initiated coverage on shares of argenx in a research note on Thursday, February 15th. They issued a “peer perform” rating for the company. Truist Financial boosted their target price on shares of argenx from $370.00 to $440.00 and gave the company a “buy” rating in a research note on Tuesday, March 5th. Finally, HC Wainwright reiterated a “buy” rating and issued a $451.00 target price on shares of argenx in a research note on Thursday, April 18th. One research analyst has rated the stock with a sell rating, five have assigned a hold rating, fourteen have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $528.16.

argenx Profile

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren's syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis.